尼洛替尼联合或不联合阿糖胞苷治疗费城染色体阳性急性淋巴细胞白血病
GRAAPH-2014随机试验在费城染色体阳性急性淋巴细胞白血病成人中比较尼洛替尼联合或不联合阿糖胞苷巩固治疗,主要终点为第4周期后主要分子学反应率。156例入组后因研究组复发过多提前暂停随机化,可评估155例中A组76例接受阿糖胞苷、B组79例未接受。两组主要分子学反应率分别为71.1%与77.2%,达到非劣效终点;但B组4年累积复发率高于A组,无复发生存更低,总生存无显著差异。
要点
- 可评估155例中A组76例接受阿糖胞苷、B组79例未接受,133例(85%)接受干细胞移植。
- 第4周期后主要分子学反应率A组71.1%、B组77.2%,达到非劣效终点。
- 4年累积复发率B组31.3% vs A组13.2%(P=0.017),B组无复发生存更低。
核心结论
- 尽管主要分子学反应率非劣效,省略阿糖胞苷后观察到更多复发,但总生存无显著影响。
- 因研究组复发过多,数据与安全监察委员会决定暂停随机化。
研究设计与样本
- GRAAPH-2014为随机试验,计划入组265例,实际入组156例后暂停随机化。
- 可评估患者155例,A组76例巩固期接受阿糖胞苷,B组79例未接受。
- 所有患者均有资格接受异基因干细胞移植,达到主要分子学反应者可接受自体干细胞移植,两种情况下均后续2年伊马替尼维持治疗。
主要发现
- 133例(85%)接受干细胞移植,其中异基因93例、自体40例。
- 主要分子学反应率A组71.1% vs B组77.2%,达到非劣效终点。
- 4年累积复发率B组31.3%(95%CI 21.1%-41.9%)vs A组13.2%(95%CI 6.7%-21.9%),P=0.017。
- 中位随访3.8年,4年总生存率A组79.0%(95%CI 70.6%-89.3%)vs B组73.4%(95%CI 63.9%-84.4%),P=0.35。
局限性
- 计划入组265例,实际入组156例后因研究组复发过多由数据与安全监察委员会决定暂停随机化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We previously demonstrated that a reduced-intensity chemotherapy schedule can safely replace hyper-CVAD (cyclophosphamide-vincristine-doxorubicin [Adriamycin]-dexamethasone) cycle 1 when combined with imatinib in adults with Philadelphia-positive acute lymphoblastic leukemia. In the present randomized GRAAPH-2014 trial, we used nilotinib and addressed the omission of cytarabine (Ara-C) in consolidation. The primary objective was the major molecular response (MMR) rate measured by BCR::ABL1 quantification after cycle 4 (end of consolidation). All patients were eligible for allogeneic stem cell transplant (SCT), whereas those in MMR could receive autologous SCT, followed by 2-year imatinib maintenance in both cases. After the enrollment of 156 of 265 planed patients, the data and safety monitoring board decided to hold the randomization because of an excess of relapse in the investigational arm. Among the 155 evaluable patients, 76 received Ara-C during consolidation (arm A) and 79 did not (arm B). Overall, 133 patients (85%) underwent SCT, 93 allogeneic and 40 autologous. The noninferiority end point regarding MMR was reached with 71.1% (arm A) and 77.2% (arm B) of patients reaching MMR. However, the 4-year cumulative incidence of relapse was higher in arm B compared with arm A (31.3% [95% confidence interval {CI}, 21.1%-41.9%] vs 13.2% [95% CI, 6.7%-21.9%]; P = .017), which translated to a lower relapse-free survival. With a median follow-up of 3.8 years, 4-year overall survival was 79.0% (95% CI, 70.6%-89.3%) in arm A vs 73.4% (95% CI, 63.9%-84.4%) in arm B (P = .35). Despite a noninferior rate of MMR, more relapses were observed when ARA-C was omitted without impact on survival. ClinicalTrials.gov ID, NCT02611492.
引用
- Chalandon Y, Rousselot P, Chevret S, et al. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia. Blood. 2024. PMID: 38452207. doi:10.1182/blood.2023023502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。